Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 27;9(8):2320-2322.
doi: 10.1016/j.ekir.2024.05.028. eCollection 2024 Aug.

Key Points in Managing PLA2R-Associated Membranous Nephropathy

Raja Ramachandran  1 , Vivekanand Jha  2   3   4 , Bhadran Bose  5
Affiliations
Editorial

Key Points in Managing PLA2R-Associated Membranous Nephropathy

Raja Ramachandran et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO clinical practice guideline for the management of Glomerular diseases. Kidney Int Suppl. 2021;100:S1–S276. doi: 10.1016/j.kint.2021.05.021. - DOI - PubMed
    1. Fernandez-Juarez G., Rojas-Rivera J., Logt A.V., et al. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Kidney Int. 2021;99:986–998. doi: 10.1016/j.kint.2020.10.014. - DOI - PubMed
    1. Fervenza F.C., Appel G.B., Barbour S.J., et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36–46. doi: 10.1056/NEJMoa1814427. - DOI - PubMed
    1. Lionaki S., Derebail V.K., Hogan S.L., et al. Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol. 2012;7:43–51. doi: 10.2215/CJN.04250511. - DOI - PMC - PubMed
    1. van de Logt A.E., Dahan K., Rousseau A., et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 2018;93:1016–1017. doi: 10.1016/j.kint.2017.12.019. - DOI - PubMed

Publication types

LinkOut - more resources